The global bleeding disorders treatment market is projected to reach USD 15.09 billion by 2021 from USD 10.33 billion in 2016, at a CAGR of 7.9% from 2016 to 2021. The increasing acceptance for prophylaxis treatment among all age groups, rising volume of diagnosed patients, and increasing R&D investments for the development of hemophilia products are driving the global market for bleeding disorders treatment. On the other hand, high costs for bleeding disorder treatment products is a major factor expected to restrain the growth of this market during the forecast period.
The global bleeding disorders treatment market is broadly classified by type and drug class. The hemophilia A segment is projected to register a healthy CAGR during the forecast period. The large number of patients suffering from hemophilia A and rising R&D investment for hemophilia products
The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the bleeding disorders treatment market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.
Geographically, the bleeding disorders treatment market is dominated by North America, followed by Europe. The increasing acceptance of prophylaxis treatment across all age groups is a key factor driving the North American bleeding disorder treatment market.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
- Market Penetration: Comprehensive information on the product portfolios of the top players in the bleeding disorders treatment market. The report analyses the bleeding disorders treatment market by type, drug class, and geography/ region. - Product Development/Innovation: Detailed insights on the pipeline products, R&D activities, and new product launches in the bleeding disorders treatment market. - Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the bleeding disorders treatment market. - Market Development: Comprehensive information about emerging markets. This report analyzes the market for various bleeding disorder treatment market products across geographies. - Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bleeding disorders treatment market.
Our reports have been used by over 10K customers, including:
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role...
17 pages •
By Euromonitor International
• Jan 2021
Natural increase will be the sole driver of population expansion in the Dominican Republic up to 2040. While ageing will be a key trend, with rapid growth in the elderly and a decline in the younger age groups, the country will remain relatively young as birth rates remain comparatively high. Nevertheless, as population composition alters...
Healthy future: Despite the mounting likelihood of new regulation, industry revenue will likely grow Abstract Cryogenic Biobanking Services Since the landmark scientific achievement of human genome sequencing in 2003, the Cryogenic Biobanking Services industry is increasingly viewed as the link between...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029
Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
Anatomic pathology market to register a CAGR of 7.1% from 2020 to 2025. The global anatomic pathology market size is projected to reach a value of USD 46.8 billion by 2025 from USD 33.3 billion in 2020, at a CAGR of 7.1% during the forecast period. The growth in this market is attributed to the high incidence of cancer...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.